Slide 1Slide 2Slide 3Slide 4Slide 5Slide 6Slide 7Slide 8Slide 9Slide 10Slide 11VITILIGOApril 26th, 1999Chemistry 412Rick HelgemoWhat is vitiligo?What is vitiligo?Autoimmune disorderGenetic linkAffects 1-2% of populationDifficult to cureHarmful effects““Untreated” VitiligoUntreated” VitiligoAutoimmune disorderAutoimmune disorderMelanocytes destroyed*Melanocyte-specific differentiation antigens*Tyrosinase, Dopachrome isomerase (TRP-2), gp100, MART-1Immunoglobulin G recognizes TRP-2, causing immune responsePossible link to curing melanoma?Genetic LinksGenetic LinksTwo types-Segmental and nonsegmentalPolygenic nature, multifactorial inheritanceAutosomal and not linked to race or sexLinked to other autoimmune diseasesWeakly heritableCuring Vitiligo EffectsCuring Vitiligo EffectsLong and difficult process, rarely 100% effective on individualAlways involves sunlight or ultraviolet lightPhysical and chemical methodsCosmeticsDepigmentationPsychological counselingChemical Treatment Options for Chemical Treatment Options for VitiligoVitiligoCorticoidsPsoralens (PUVA)PhenylalanineP-aminobenzoic acid (PABA)Cantharidin, a blister beetle secretionPhysical Treatment Options for Physical Treatment Options for VitiligoVitiligoTattooing (micropigmentation)Autologous skin graftsSkin grafting using blistersAutologous melanocyte transplantationCombination of Sun and SunscreenReferences:References:§“Anti-tyrosinase-related protein-2 immune response in vitiligo patients…;” Okamoto T, Irie RF, Fujii S, etal.; The Journal of Investigative Dermatology; Dec 1998; 111:1034-1039.§“Autoantibodies to Tyrosinase-related protein-1 detected in the sera… ;” Kemp EH, Waterman EA, Gawkrodger DJ, et al.; British Journal of Dermatology 1998; 139:798-805.§“A systematic review of autologous transplantation methods in vitiligo;” Njoo MD,Westerhof W, Bos JD, Bossuyt PMM; Archives of Dermatology, Dec 1998 134:1543-1549.§“The genetics of vitiligo in Korean patients;” Kim SM, Chung HS, Hann SK; International Journal of Dermatology 1998; 38:908-910.§“On the association between vitiligo and malignant melanoma;” Lindelof B, Hedblad MA, Sigurgeirsson B; Acta Dermatologica Venereologica; 1998 78:483-484. §“Tyrosinase as an autoantigen in patients with vitiligo;” Baharav E, Merimsky O, Shoenfeld Y, et al.; Clinical Experimental Immunology; 1996 105:84-88.§“Nonsurgical repigmentation therapies in vitiligo;” Njoo MD,Westerhof W, Bos JD, Bossuyt PMM; Archives of Dermatology; Dec 1998 134:1532-1540.§“Spontaneous repigmentation of vitiligo patches distant from the autologous skin…;” Malakar S, Dhar S;Dermatology; 1998 197:274.More ReferencesMore References§“Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience;” Camacho F, Mazuecos J; Archives of Dermatology; Feb 1999 135:216-217.§“UV-dependent melanocyte plasticity-The structure-function relationship;” Iyengar B; Indian Journal of Pathological Microbiology; 1996 39(2):105-109.§“Topical application of a melanotropin analogue to vulgar vitiligo dermo-epidermal minigrafts;” Schwartzmann-Solon AM, Visconti MA, Castrucci AML; Brazilian Journal of Medical and Biological Research; 1998 31:1557-1564.§“Repigmentation of vitiligo lesion after beetle dermatitis;” Parsad D, Saini R, Nagpal R; Dermatology; 1998
View Full Document